| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Crizotinib | CCLE | pan-cancer | AAC | 0.014 | 0.8 |
| mRNA | ISOX | CTRPv2 | pan-cancer | AAC | 0.0093 | 0.8 |
| mRNA | Nilotinib | CCLE | pan-cancer | AAC | 0.015 | 0.8 |
| mRNA | BRD-A05715709 | CTRPv2 | pan-cancer | AAC | -0.016 | 0.8 |
| mRNA | alisertib:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.01 | 0.8 |
| mRNA | PIK-93 | GDSC1000 | pan-cancer | AAC | -0.0081 | 0.8 |
| mRNA | BI-2536 | GDSC1000 | pan-cancer | AAC | 0.015 | 0.8 |
| mRNA | paclitaxel | UHNBreast | pan-cancer | AAC | -0.089 | 0.8 |
| mRNA | ZM-447439 | GDSC1000 | pan-cancer | AAC | 0.01 | 0.8 |
| mRNA | darinaparsin | CTRPv2 | pan-cancer | AAC | 0.014 | 0.8 |